Two studies led by researchers at the American Cancer Society showed an increase in the use of proton beam therapy for patients with cancer in the U.S. during the past decade.
A study led by researchers at ACS showed cancer survivors in the United States who reported medical financial hardship have a higher mortality risk than cancer survivors without financial hardship. Medical financial hardship was measured as problems affording health care or delaying or forgoing any health care due to cost in the past 12 months.
Findings led by researchers at the American Cancer Society show that five-year survivors of adolescent and young adult cancer in the United States have a higher risk of developing and nearly double the risk of dying from a new primary cancer as the general population.
Access to therapies approved over the last decade has significantly lengthened median survival times in patients with metastatic hormone-sensitive prostate cancer, according to a large randomized clinical trial conducted by researchers from SWOG Cancer Research Network.
The American Society of Clinical Oncology published new guidelines to support clinicians in managing immune-related adverse events in adult cancer patients treated with CAR T-cell therapy.
Researchers from the Gwangju Institute of Science and Technology have developed a deep learning model that predicts unexpected drug-drug interactions (DDIs) based on their effects on gene expression.
Breast cancer screening and early detection efforts have contributed to improved survival in recent decades, as breast cancer is more easily treated at early stages. But not all women have benefited equally.
A phase Ib study by MD Anderson researchers demonstrated that targeting angiogenesis drivers—such as delta-like ligand 4 (DLL4)—may improve responses to vascular endothelial growth factor (VEGF) inhibitors and may lead to improved outcomes in patients with platinum-resistant ovarian cancer (PROC).
Enhertu (fam-trastuzumab deruxtecan-nxki) received FDA regular approval for adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy.
FDA granted Priority Review for Imfinzi (durvalumab) in combination with standard-of-care chemotherapy, for patients with locally advanced or metastatic biliary tract cancer (BTC).
